NO20080661L - Nye cystein-protease-inhibitorer og deres terapeutiske anvendelser - Google Patents

Nye cystein-protease-inhibitorer og deres terapeutiske anvendelser

Info

Publication number
NO20080661L
NO20080661L NO20080661A NO20080661A NO20080661L NO 20080661 L NO20080661 L NO 20080661L NO 20080661 A NO20080661 A NO 20080661A NO 20080661 A NO20080661 A NO 20080661A NO 20080661 L NO20080661 L NO 20080661L
Authority
NO
Norway
Prior art keywords
protease inhibitors
therapeutic applications
cysteine protease
novel cysteine
novel
Prior art date
Application number
NO20080661A
Other languages
English (en)
Norwegian (no)
Inventor
Philippe Guedat
Guillaume Boissy
Catherine Borg-Capra
Frederic Colland
Laurent Daviet
Etienne Formstecher
Xavier Jacq
Jean-Christophe Rain
Remi Delansorne
Stefania Vallese
Matteo Colombo
Original Assignee
Hybrigenics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05291683A external-priority patent/EP1749822B1/en
Priority claimed from US11/197,525 external-priority patent/US20070032499A1/en
Application filed by Hybrigenics Sa filed Critical Hybrigenics Sa
Publication of NO20080661L publication Critical patent/NO20080661L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
NO20080661A 2005-08-05 2008-02-07 Nye cystein-protease-inhibitorer og deres terapeutiske anvendelser NO20080661L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05291683A EP1749822B1 (en) 2005-08-05 2005-08-05 Novel cysteine protease inhibitors and their therapeutic applications
US11/197,525 US20070032499A1 (en) 2005-08-05 2005-08-05 Novel cysteine protease inhibitors and their therapeutic applications
PCT/IB2006/002637 WO2007017758A2 (en) 2005-08-05 2006-07-26 Novel cysteine protease inhibitors and their therapeutic applications

Publications (1)

Publication Number Publication Date
NO20080661L true NO20080661L (no) 2008-03-04

Family

ID=37507720

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080661A NO20080661L (no) 2005-08-05 2008-02-07 Nye cystein-protease-inhibitorer og deres terapeutiske anvendelser

Country Status (16)

Country Link
US (1) US8648076B2 (ja)
EP (1) EP1912954B1 (ja)
JP (2) JP5523703B2 (ja)
AT (1) ATE501127T1 (ja)
AU (1) AU2006277678B2 (ja)
CA (1) CA2617725C (ja)
DE (1) DE602006020585D1 (ja)
DK (1) DK1912954T3 (ja)
ES (1) ES2363743T3 (ja)
IL (1) IL189286A (ja)
NO (1) NO20080661L (ja)
NZ (1) NZ565670A (ja)
PL (1) PL1912954T3 (ja)
RU (1) RU2424234C2 (ja)
UA (1) UA96269C2 (ja)
WO (1) WO2007017758A2 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617725C (en) * 2005-08-05 2012-04-03 Hybrigenics Sa Novel cysteine protease inhibitors and their therapeutic applications
AU2007315885B2 (en) * 2006-10-30 2013-01-31 Hybrigenics Sa Novel tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
EP2824113B1 (en) 2013-07-09 2017-05-03 Samsung Electronics Co., Ltd Biomarker for selecting a subject for application of an anti-c-met antibody
US9567510B2 (en) 2014-09-11 2017-02-14 Halliburton Energy Services, Inc. Cyanamide-based carbon dioxide and/or hydrogen sulfide scavengers and methods of use in subterranean operations
EP3375779B1 (en) * 2015-11-10 2022-09-07 Kyushu University National University Corporation 2,3-dicyanopyrazine compound, luminescent material and light transmitter using the same
WO2021170290A1 (en) * 2020-02-28 2021-09-02 Immunologik Gmbh Inhibitors of human deubiquitinases for the treatment of coronaviral infections

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3219339B2 (ja) * 1993-06-15 2001-10-15 株式会社リコー ピラジン化合物及びそれを含有する電子写真感光体
JPH0798508A (ja) * 1993-09-28 1995-04-11 Ricoh Co Ltd 単層型電子写真感光体
JPH07175235A (ja) 1993-12-20 1995-07-14 Ricoh Co Ltd 単層型電子写真用感光体
JP3255525B2 (ja) 1993-12-23 2002-02-12 株式会社リコー ピラジン化合物及びそれを含有する電子写真感光体
JPH07199486A (ja) 1993-12-30 1995-08-04 Ricoh Co Ltd 電子写真用感光体
JPH07199487A (ja) 1993-12-30 1995-08-04 Ricoh Co Ltd 電子写真用感光体
JPH07281460A (ja) 1994-04-14 1995-10-27 Ricoh Co Ltd 潜像転写用電子写真感光体
CN1245486A (zh) * 1996-12-11 2000-02-23 Basf公司 用作钙蛋白酶抑制剂的酮苯甲酰胺
JP2000128885A (ja) 1998-10-19 2000-05-09 Ricoh Co Ltd テトラピラジノポルフィラジン化合物及びその製造方法
JP2000122316A (ja) 1998-10-19 2000-04-28 Ricoh Co Ltd 電子写真感光体
JP2001028885A (ja) 1999-07-12 2001-01-30 Sanyo Electric Co Ltd 電源装置
US20040109690A1 (en) * 2001-01-30 2004-06-10 Yoshinobu Maeda Optical control method and device
AU2002305926A1 (en) * 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
HUP0402344A2 (hu) * 2001-12-04 2005-02-28 F. Hoffmann-La Roche Ag Helyettesített 2-amino-cikloalkán-karboxamidok, felhasználásuk cisztein-proteáz-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
WO2003055853A1 (fr) 2001-12-26 2003-07-10 Nippon Soda Co., Ltd. Composes accepteurs d'electrons pouvant former des monocouches autoassemblees
AU2003266052B2 (en) * 2002-09-04 2009-04-23 Merck Frosst Canada Ltd Cathepsin cysteine protease inhibitors
CA2617725C (en) * 2005-08-05 2012-04-03 Hybrigenics Sa Novel cysteine protease inhibitors and their therapeutic applications

Also Published As

Publication number Publication date
AU2006277678B2 (en) 2012-04-19
DK1912954T3 (da) 2011-05-23
RU2008108501A (ru) 2009-09-10
JP2009503052A (ja) 2009-01-29
CA2617725C (en) 2012-04-03
CA2617725A1 (en) 2007-02-15
AU2006277678A1 (en) 2007-02-15
PL1912954T3 (pl) 2011-09-30
ATE501127T1 (de) 2011-03-15
EP1912954A2 (en) 2008-04-23
US8648076B2 (en) 2014-02-11
IL189286A0 (en) 2008-06-05
WO2007017758A3 (en) 2007-04-19
JP5523703B2 (ja) 2014-06-18
EP1912954B1 (en) 2011-03-09
ES2363743T3 (es) 2011-08-12
WO2007017758A2 (en) 2007-02-15
JP2013166798A (ja) 2013-08-29
UA96269C2 (uk) 2011-10-25
RU2424234C2 (ru) 2011-07-20
IL189286A (en) 2013-08-29
US20090215786A1 (en) 2009-08-27
DE602006020585D1 (de) 2011-04-21
NZ565670A (en) 2010-01-29

Similar Documents

Publication Publication Date Title
NO20090628L (no) Pyridizinon derivativater
CY1114916T1 (el) Μεθοδοι
NO20075647L (no) Kjemiske forbindelser
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
EA201070247A1 (ru) Ингибиторы протеасом
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
CY1113560T1 (el) Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
DE602005010421D1 (de) Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
EA200701467A1 (ru) Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
EA200700717A1 (ru) Сульфонамиды
EA200701840A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
NO20082266L (no) Nye 1-azabicykloalkylderivater for behandling av psykotiske og neurodegenerative forstyrrelser
NO20063944L (no) Piperidinylkarbonyl-pyrrolidiner og deres anvendelse som melanokortinagonister
NO20073368L (no) Amid-promedikament av gemcitabin, sammensetninger og anvendelse derav
EA200801199A1 (ru) Ингибиторы киназы
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater
NO20080661L (no) Nye cystein-protease-inhibitorer og deres terapeutiske anvendelser
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
SE0403085D0 (sv) Novel componds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application